CML (chronic myeloid leukaemia) is characterized by the presence of the oncogenic tyrosine kinase fusion protein BCR (breakpoint cluster region)–Abl, responsible for driving the disease. Current TKI (tyrosine kinase inhibitor) therapies effectively inhibit BCR–Abl to control CML in the majority of patients, but do not eliminate the LSC (leukaemic stem cell) population, which becomes quiescent following treatment. Patients require long-term treatment to sustain remission; alternative strategies are therefore required, either alone or in combination with TKIs to eliminate the LSCs and provide a cure. The embryonic morphogenetic pathways play a key role in haemopoiesis with recent evidence suggesting LSCs are more dependent on these signals following chemotherapy than normal HSCs (haemopoietic stem cells). Recent evidence in the literature and from our group has revealed that the BMP (bone morphogenetic protein) pathway is differentially expressed in CML patients compared with normal donors. In the present review, we explore the role that BMP signalling plays in oesteoblast differentiation, HSC maintenance and the implication of altered BMP signalling on LSC persistence in the BM (bone marrow) niche. Overall, we highlight the BMP pathway as a potential target for developing LSC-directed therapies in CML in the future.
Skip Nav Destination
Article navigation
August 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
August 11 2014
The role of the bone morphogenetic proteins in leukaemic stem cell persistence
Parto Toofan;
Parto Toofan
*Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, 1053 Great Western Road, Glasgow G12 0XB, U.K.
Search for other works by this author on:
David Irvine;
David Irvine
*Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, 1053 Great Western Road, Glasgow G12 0XB, U.K.
Search for other works by this author on:
Lisa Hopcroft;
Lisa Hopcroft
*Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, 1053 Great Western Road, Glasgow G12 0XB, U.K.
Search for other works by this author on:
Mhairi Copland;
Mhairi Copland
*Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, 1053 Great Western Road, Glasgow G12 0XB, U.K.
Search for other works by this author on:
Helen Wheadon
Helen Wheadon
1
*Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, 1053 Great Western Road, Glasgow G12 0XB, U.K.
1To whom correspondence should be addressed (emailhelen.wheadon@glasgow.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 05 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (4): 809–815.
Article history
Received:
February 05 2014
Citation
Parto Toofan, David Irvine, Lisa Hopcroft, Mhairi Copland, Helen Wheadon; The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochem Soc Trans 1 August 2014; 42 (4): 809–815. doi: https://doi.org/10.1042/BST20140037
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.